51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

  
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05029336
(ClinicalTrials.gov)
September 202324/8/2021Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesAutologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Autoimmune DiseasesSystemic Lupus Erythematosus;Systemic SclerosisBiological: Depletion of CD3/CD19 in an autologous stem cell transplantStephan Grupp MD PhDNULLRecruiting8 Years25 YearsAll20Phase 2United States
2EUCTR2022-001484-27-NL
(EUCTR)
24/01/202329/10/2022Basta 2B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis TissuesAnalysis 2 - Basta 2 Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam
Product Code: IND 127861
INN or Proposed INN: [89Zr]Zr-Df-crefmirlimab berdoxam
Other descriptive name: Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89
radboudumcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Netherlands
3NCT05270668
(ClinicalTrials.gov)
February 22, 202227/2/2022Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)Diffuse Cutaneous Systemic Sclerosis;Interstitial Lung DiseaseDrug: PRA023 IV;Device: Companion diagnostic ( CDx);Drug: PlaceboPrometheus Biosciences, Inc.NULLRecruiting18 YearsN/AAll100Phase 2United States;Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom
4NCT05085444
(ClinicalTrials.gov)
October 8, 202111/10/2021A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory SclerodermaA Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory SclerodermaScleroderma;Autoimmune DiseasesBiological: Assigned Interventions CD19/BCMA CAR T-cellsZhejiang UniversityYake Biotechnology Ltd.RecruitingN/AN/AAll9Early Phase 1China
5JPRN-jRCTc071190041
04/01/201909/01/2020A clinical trial of autologous stem cell transplantation for severe systemic sclerosisA single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis - A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis systemic sclerosisAfter peripheral blood stem cell mobilization and aphereisi with cyclophosphamide 4 g/m2 and G-CSF, CD34+ cells were enriched by using anti-CD34 immunomagnetic beads. Conditioning was performed using high-dose cyclophosphamide (50 mg/kg) for 4 days, and freeze-thawed CD34+ cells were transplanted.Akashi KoichiNULLNot Recruiting>= 16age old< 65age oldBoth12Phase 2Japan
6NCT03630211
(ClinicalTrials.gov)
July 31, 20187/8/2018Autologous Stem Cell Transplantation in Patients With Systemic SclerosisAutologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)Systemic Sclerosis;Diffuse Sclerosis Systemic;Interstitial Lung Disease;Pulmonary HypertensionDrug: Cyclophosphamide;Drug: Mesna;Drug: Rituximab;Drug: Alemtuzumab;Drug: Thiotepa;Drug: GM-CSF;Drug: Intravenous immunoglobulin;Radiation: Total Body Irradiation;Drug: Anti Thymocyte GlobulinPaul SzabolcsNULLRecruiting8 Years60 YearsAll8Phase 2United States
7NCT01895244
(ClinicalTrials.gov)
September 20121/7/2013Autologous Stem Cell Transplantation for Progressive Systemic SclerosisHighdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to ManifestationScleroderma;Cardiac Involvement;Autologous Stem Cell TransplantationDrug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cellsUniversity Hospital TuebingenNULLActive, not recruiting18 Years65 YearsAll44Phase 2Germany
8EUCTR2011-002434-40-DE
(EUCTR)
23/03/201218/08/2011Transplantation of stem cells for the treatment of svere systemic sclerosis with a protocol which is adapted to individual manifestatons of the diseaseHighdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosisModification according to manifestation - AST-MOMA Systemic sclerosis
MedDRA version: 14.1;Level: LLT;Classification code 10059040;Term: Autologous peripheral haematopoietic stem cell transplant;System Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: CD34 selected autologous hematopoietic cells
Product Code: CD34+SC
University Hospital TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany
9NCT01086540
(ClinicalTrials.gov)
June 24, 201111/3/2010Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)Systemic Sclerosis-Associated PAHBiological: Rituximab;Other: Placebo;Diagnostic Test: CMRI;Drug: prednisone;Drug: methylprednisolone;Drug: diphenhydramine;Drug: acetaminophenNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.Completed18 Years75 YearsAll57Phase 2United States
10NCT00936546
(ClinicalTrials.gov)
June 20099/7/2009A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyA Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyDebilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)Drug: RituximabUniversity Hospital, GhentNULLCompleted18 YearsN/AAll3Phase 2Belgium
11EUCTR2008-007180-16-NL
(EUCTR)
13/05/200924/11/2008INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA - RItuximab In Scleroderma ( RITIS)INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA - RItuximab In Scleroderma ( RITIS) systemic sclerosis
MedDRA version: 9.1;Level: PT;Classification code 10039710;Term: Scleroderma
Trade Name: Rituximab
Product Name: Mabthera
LUMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
12NCT00379431
(ClinicalTrials.gov)
November 27, 200620/9/2006A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), RituximabA Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), RituximabEarly and Severe Systemic SclerosisDrug: Administration of rituximab and methylprednisoloneUniversity Hospital, GhentNULLCompleted18 YearsN/AAll9Phase 2Belgium
13EUCTR2006-003836-31-BE
(EUCTR)
06/09/200602/08/2006A protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximabA protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximab systemic sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10042953;Term: Systemic sclerosis
Trade Name: MabThera
Product Name: Rituximab
INN or Proposed INN: Rituximab
University Hospital GentNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Belgium
14NCT00114530
(ClinicalTrials.gov)
June 200515/6/2005Scleroderma: Cyclophosphamide or Transplantation (SCOT)A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)Scleroderma, Systemic;Sclerosis;Autoimmune DiseaseBiological: mHSCT;Drug: cyclophosphamideNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years69 YearsAll75Phase 2/Phase 3United States;Canada